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The Fgf-3 protooncogene (previously called int-2) is a target of proviral insertion mutations in mammary tumors induced
by the mouse mammary tumor virus (MMTV). These insertion mutations result in the transcriptional activation of Fgf-3,
which is not normally expressed in the adult mammary gland. Previous mapping studies of numerous Fgf-3 insertion
mutations have failed to reveal any provirus integrations within the gene coding region. This finding is consistent with the
hypothesis that oncogenesis occurs in this system as a consequence of up-regulation of Fgf-3 transcription, rather than
from alterations of the gene product. During an analysis of a new cohort of tumors from the WXG-2 mouse strain, a breast
tumor was identified which had a MMTV provirus integrated 24 bp upstream of the Fgf-3 stop codon. This insertion mutation
generated a fusion transcript which was readily detectable in tumor RNA by RT-PCR. The predicted protein product of this
fusion transcript is missing 8 aa of native sequence and contains an additional 8 aa of cryptic MMTV-encoded sequence.
These data document the first exception to the generalization that the Fgf-3 coding region is not disrupted by MMTV
insertion mutation. q 1997 Academic Press
The mouse mammary tumor virus (MMTV) causes These data support the model that the pathogenic effects
of Fgf-3 insertion mutations are a result of unscheduledmammary adenocarcinomas in susceptible strains of
mice by mutating host genes at provirus integration sites transcription controlled by cis-acting regulatory elements
within the MMTV genome (Nusse et al., 1984; Clausse(Dickson, 1990; Morris, 1991; Nusse, 1991; Peters, 1991;
Callahan, 1996). One of the genes which is frequently et al., 1993a). Such effects on Fgf-3 gene expression can
occur over distances as great as 20 kb (Peters et al.,mutated by MMTV insertion is the Fgf-3 protooncogene
(Dickson et al., 1990a, 1991; Dickson and Fantl, 1994). 1989a; Morris et al., 1990). There is currently no evidence
indicating that point mutations occur in Fgf-3 allelesFgf-3 is a member of the fibroblast growth factor gene
family (Dickson and Peters, 1987). The gene is postulated which have suffered insertion mutations.
We are in the process of analyzing a new cohort ofto function during embryogenesis (Jakobovits et al., 1986;
MMTV-induced breast tumors from the WXG-2 mouseWilkinson et al., 1988; 1989) and is not expressed in the
strain (Morris et al., 1986). This strain carries the patho-adult mammary gland (Dickson et al., 1984).
genic Mtv-2 provirus on an endogenous MMTV-free ge-To date, the integration sites of more than 85 insertion
netic background derived from endogenous and exoge-mutations of the Fgf-3 locus have been mapped by sev-
nous MMTV-free wild mice from Lake Casitas, Californiaeral laboratories (Peters et al., 1986, 1989a; Morris et
(Cohen and Varmus, 1979; Cohen et al., 1982). One partic-al., 1990; Marchetti et al., 1991; Clausse et al., 1993b;
ular tumor (1707) was found to have an insertion mutationShackleford et al., 1993). Most insertion mutations occur
which unexpectedly localized to the carboxyl end of theupstream of the gene with the provirus and Fgf-3 in oppo-
Fgf-3 coding region.site transcriptional orientations or downstream of the
To precisely characterize the Fgf-3 mutation in tumorgene with the provirus and Fgf-3 in the same transcrip-
1707, PCR was used to amplify genomic DNA from thetion orientation. Occasional insertion mutations are ob-
mutated allele which spanned the 5* host/virus junctionserved within the 3* untranslated region of the tran-
(Fig. 1A). This amplification product was subsequentlyscribed sequences (at least 15 such examples have been
cloned and sequenced (Fig. 1B). Briefly, genomic DNAmapped). In all cases, the insertion mutations have left
was extracted from frozen tumor tissue using the SNAP-the protein coding region intact (Dickson et al., 1990b).
O-SOL system from BIOTECX (Houston, TX), according
to the manufacturer’s instructions. PCR amplification was1 To whom correspondence should be addressed at Department of
performed using 200 ng of genomic DNA in a total vol-Medical Pathology, Tupper Hall, Room 3327, University of California,
Davis, Davis, CA 95616. E-mail: dwmorris@ucdavis.edu. ume of 100 ml containing 11 Qiagen PCR buffer with 1.5
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FIG. 1. (A) Amplification of the 5* host/virus junction fragment from the MMTV insertion mutation of Fgf-3 in WXG-2 tumor 1707. PCR analysis of
genomic DNA from tumor 1707 was performed as described in the text. Lane 1, amplification product from the mutated Fgf-3 allele. Lane 2; 100-
bp marker from Life Technologies. (B) Nucleic acid sequence of the 5* host/virus junction fragment from the MMTV insertion mutation of Fgf-3 in
WXG-2 tumor 1707. Nucleotide sequence and translation of the host virus junction fragment from A is shown. The primer locations are underlined
and the 6-bp direct repeat of host DNA at the provirus integration site is boxed. The 18 aa encoded by the Fgf-3 gene are indicated in lightface
lettering and the 8 aa encoded by MMTV are indicated in boldface lettering.
mM MgCl2 (Chatsworth, CA), 100 mM dNTPs, 25 U/ml Fasel et al. (1982) (coordinates 207 to 188 relative to the
start of the 5* LTR). All primers were purchased fromQiagen Taq Polymerase, and 0.2 mM of each of the ampli-
fication primers. The reactions were performed for 30 Integrated DNA Technologies (Coralville, IA). The ampli-
fied junction fragment was cloned using a TA Cloningcycles in an Amplitron II thermal cycler from Thermolyne
(Dubuque, IA), with denaturation, annealing, and exten- Kit from Invitrogen (Carlsbad, CA) and miniprep DNAs
were prepared for sequencing using the Wizard PLUSsion temperatures of 95, 55, and 727, respectively. The
Fgf-3 coding strand primer was pr24.13 (5*-GTGAT Minipreps DNA Purification System from Promega (Madi-
son, WI), both according to the manufacturer’s instruc-CATGG CAAGA TGGAG-3*) at coordinates 5972 to 5991
in the sequence Moore et al. (1986). The MMTV template tions. Miniprep DNAs were screened by PCR using the
original amplification protocol on approximately 25 ng ofstrand primer was pr24.6 (5*-GAGCA CGAAC CGCAA
CTTCC-3*) at coordinates 239 to 220 in the sequence of plasmid DNA, and both strands of two positive colonies
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were sequenced by the University of California, Davis
DBS Automated DNA Sequencing Facility using PRISM
sequencers, reagents, and software from ABI (Foster
City, CA). In addition, the 3* junction fragment was cloned
and sequenced using similar procedures (data not
shown). The nucleotide sequence of the junction frag-
ment has been submitted to the GenBank nucleotide
sequence database and has been assigned Accession
No. AF009658.
The sequence of the 5* host/virus junction fragment is
shown in Fig. 1B. It corresponds exactly to the previously
published sequences of MMTV and Fgf-3, except at posi-
tion 232 where we found a difference with the MMTV
sequence of Fasel et al. (1982). To resolve the anomaly, FIG. 2. Detection of the Fgf-3/MMTV hybrid transcript in WXG-2 tumor
1707. RT-PCR analysis of total RNA from tumor 1707 was performedthis region of the endogenous Mtv-2 provirus was also
as described in the text. Lane 1, RT deletion control (same as lane 2PCR amplified and sequenced (data not shown), demon-
without RT during cDNA synthesis). Lane 2, amplification product fromstrating that the tumor 1707 sequence matches the Mtv-
the Fgf-3/MMTV hybrid transcript. Lane 3, reagent blank (same as lane
2 provirus sequence at this position. An examination of 2 without cDNA during PCR amplification). Lane 4, 100-bp marker from
the sequence relative to the known Fgf-3 gene structure Life Technologies.
revealed that the provirus was integrated between a 6-
bp direct repeat of host DNA corresponding to positions
6022 to 6027 in the sequence of Moore et al. (1986), 24 Eight genes have now been identified (generically re-
ferred to as int genes) which are activated by MMTVbp upstream of the stop codon at position 6052. The
integration site is positioned such that the Fgf-3 coding insertion mutation in multiple independent mouse mam-
mary tumors: int-1/Wnt-1 (Nusse and Varmus, 1982), int-sequence is fused with frame 1 of the provirus. The be-
ginning of the MMTV sag gene is encoded in frame 3, 2/Fgf-3 (Peters et al., 1983), int-3/Notch4 (Gallahan and
Callahan, 1987), int-4/Wnt-3 (Roelink et al., 1990), Fgf-4/the end of the MMTV env gene is encoded in frame 2,
and the frame 1 sequence is noncoding, ending in a hstlk-FGF (Peters et al., 1989b), Fgf-8 (MacArthur et al.,
1995), int-6 (Marchetti et al., 1995), and Wnt-10b (Lee etcryptic stop codon 8 aa from the start of the LTR (Fasel
et al., 1982; Redmond and Dickson, 1983). al., 1995). The int genes sort into two groups based on
the postulated molecular mechanisms of ‘‘activation’’ byTo verify that the mutated Fgf-3 allele was expressed,
RT-PCR was used to amplify the predicted fusion tran- MMTV insertion mutation: (i) those that are activated by
transcriptional dysregulation and (ii) those that are acti-script. Briefly, total RNA was extracted from frozen tumor
tissue using the SNAP-O-SOL system from BIOTECX vated by gene product disruption (either truncation or
fusion with MMTV and/or intron encoded sequences).(Houston, TX) according to the manufacturer’s instruc-
tions. Prior to use, the total RNA was treated with ‘‘amplifi- The former group includes genes which are hypothe-
sized to have autocrine and/or paracrine effects as acation grade’’ DNase I from Life Technologies (Gaithers-
burg, MD) and repurified using a RNeasy Mini Kit from result of unscheduled expression (int-1/Wnt-1, int-2/Fgf-
3, int-4/Wnt-3, Fgf-4/hst/k-FGF, Fgf-8, and Wnt-10b), andQiagen, Inc. (Santa Clara, CA), both according to the
manufacturer’s instructions. For RT-PCR assays, cDNA the latter includes genes which are hypothesized to have
gain-of-function (int-3) or dominant-negative (int-6) phe-was made from DNase-treated total RNA using Super-
script II RNase H0 reverse transcriptase (RT) from Life notypes as a consequence of coding sequence trunca-
tions or fusions.Technologies according to the manufacturer’s instruc-
tions, except that 2 pmol of transcript-specific primer was These data establish the principle that int genes
which have oncogenic effects as a consequence of tran-substituted for the dT15-18 primer. In this case, since a
fusion transcript was predicted, cDNA synthesis was scriptional dysregulation may, in some circumstances,
also have coding region insertion mutations. Such muta-primed with the MMTV template strand primer pr24.23
(5*-GCACA GAAGA GTTAT TATTG-3*) at coordinates 284 tions appear to be rare for the known int genes, probably
due to a low tolerance for gene product alterations. Nev-to 265 in the sequence of Fasel et al. (1982) (coordinates
252 to 233 relative to the start of the 5* LTR). RT-PCR ertheless, it is theoretically possible that a new int gene
which is activated by dysregulation might be able towas performed on cDNA from 200 ng of total RNA using
primers pr24.13 and pr24.6 under the same PCR condi- withstand relatively large truncations or fusions without
losing biological activity. Accordingly, the information intions as listed above. As shown in Fig. 2, the predicted
fusion transcript was readily detectable in tumor 1707 this report may be useful during the initial characteriza-
tion of new int genes, particularly in cases of large genesRNA and, as expected, had the same size as the genomic
target shown in Fig. 1A. where a limited number of ‘‘hits’’ have been identified.
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Dickson, C., and Fantl, V. (1994). Fgf-3, an oncogene in murine breastIn such situations, conclusive discrimination between
cancer. Cancer Treat. Res. 71, 331–343.the two types of insertion mutations requires a bioassay
Dickson, C., and Peters, G. (1987). Potential oncogene product related
demonstrating an oncogenic phenotype using either the to growth factors. Nature 326, 833.
native or disrupted gene. Fasel, N., Pearson, K., Buetti, E., and Diggelmann, H. (1982). The region
of mouse mammary tumor virus DNA containing the long terminalThe 8-aa substitution at the carboxyl terminus of Fgf-
repeat includes a long coding sequence and signals for hormonally3 in tumor 1707 falls within a region that is not evolution-
regulated transcription. EMBO J. 1, 3–7.arily conserved (Kiefer et al., 1996). Therefore, it is possi-
Gallahan, D., and Callahan, R. (1987). Mammary tumorigenesis in feral
ble that this portion of the protein is not necessary for mice: Identification of a new int locus in mouse mammary tumor
biological activity and can withstand replacement without virus (Czech II)-induced mammary tumors. J. Virol. 61, 66–74.
Jakobovits, A., Shackleford, G. M., Varmus, H. E., and Martin, G. R.the loss of oncogenic function. Because the predicted
(1986). Two proto-oncogenes implicated in mammary carcinogene-fusion protein has the same length as the native protein,
sis, int-1 and int-2, are independently regulated during mouse devel-it is interesting to speculate that there may be some
opment. Proc. Natl. Acad. Sci. USA 83, 7806–7810.
length constraint on mutations affecting the carboxyl ter- Kiefer, P., Strahle, U., and Dickson, C. (1996). The zebrafish Fgf-3 gene:
minus due to protein folding. cDNA sequence, transcript structure and genomic organization.
Gene 168, 211–215.In summary, we have identified a clonally integrated
Lee, F. S., Lane, T. F., Kuo, A., Shackleford, G. M., and Leder, P. (1995).exogenous MMTV provirus integrated within the carboxyl
Insertional mutagenesis identifies a member of the Wnt gene familyend of the Fgf-3 coding region. This is the first example
as a candidate oncogene in the mammary epithelium of int-2/Fgf-3
of a MMTV insertion mutation in which an int gene that transgenic mice. Proc. Natl. Acad. Sci. USA 92, 2268–2272.
is typically activated by transcriptional dysregulation also MacArthur, C. A., Shankar, D. B., and Shackleford, G. M. (1995). Fgf-8,
activated by proviral insertion, cooperates with the Wnt-1 transgenehas a disrupted coding region.
in murine mammary tumorigenesis. J. Virol. 69, 2501–2507.
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